Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Airbnb Unveils Airport Pickup Service Across 125 Cities in Global Expansion - 2I binged all 24 Hallmark Christmas movies in less than 30 days. I emerged a changed man.
- 3Dental, Vision, and Hearing Inclusion in Senior Protection.
- 4Virtual reality opens doors for older people to build closer connections in real life
- 5Southern Californians, your health insurance costs could rise in 2026
- Archaeologists uncover details about the Hjortspring boat's origins
- In a first, scientists observe a comet reversing its spin
- Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.
- Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy
- The Best Competitors of the 21st Hundred years
- Italy now recognizes the crime of femicide and punishes it with life in prison
- 'Spending more on gas than groceries:' Rising fuel prices drive more San Antonio families to the Food Bank amid Iran war
- Scientists uncover an ant assassination scheme that helps a parasitic queen rise to power
- More charges filed against ex-left-wing RAF member Daniela Klette
